wellrank.ai
Olumiant logo

Olumiant

First cited by AI Jun 13, 2026

Surfaced organically in AI answers about hair loss treatment. Not yet profiled.

AI Visibility

Visibility trend

Hair loss treatment, daily share of AI answers mentioning Olumiant, through Jun 13, 2026.

8.3%

Avg position when mentioned: 6.0

By engine

Where Olumiant is strong, and where it is invisible.

  • ChatGPT
    33.3%

Mention sentiment

Tone of AI mentions across all tracked answers.

  • 1 positive mentions
  • 0 neutral
  • 0 mixed or cautious

Recent AI answers mentioning Olumiant

ChatGPTJun 13, 2026, 11:03 UTC
What is the best hair loss treatment for women?

Short answer: there’s no single “best” treatment for all women — the right option depends on the cause. For the most common problem (female pattern hair loss / androgenetic alopecia), first‑line, evidence‑based choices are topical minoxidil and anti‑androgen therapy; other effective options include PRP, low‑level laser therapy, and (for select patients) hair transplant. For alopecia areata, the newly approved JAK inhibitor baricitinib (Olumiant) and steroid injections are options. Practical, named recommendations and why they’re used Rogaine (minoxidil) Women’s 5% Foam — FDA‑approved for female pattern hair loss; improves hair density and is the usual first‑line topical treatment. It’s easy to use at home; expect 3–6 months to see results. Spironolactone (brand: Aldactone) — an oral anti‑androgen commonly prescribed off‑label for women with androgenetic hair loss or PCOS‑related hair thinning. Often effective for slowing loss and regrowing hair in androgen‑driven cases. Requires medical supervision (blood pressure, potassium, pregnancy avoidance). Low‑dose oral minoxidil (off‑label; prescribed by dermatologists) — many dermatologists now use 0.25–2.5 mg nightly when topical minoxidil isn’t sufficient. Can be very effective but needs monitoring (blood pressure, side effects). Platelet‑Rich Plasma (PRP) at a board‑certified dermatologist’s office — an in‑office procedure with growing evidence for improving hair thickness; often used as an adjunct to medical therapy. Quality varies by clinic, so choose a reputable, experienced provider. Low‑level laser devices (brands: HairMax, LaserCap) — home devices with clinical studies showing modest improvement in hair density; good adjunct or for patients wanting a non‑drug option. Hair transplant (FUE) at established clinics (examples: Bernstein Medical, reputable local hair transplant centers) — effective for stable, advanced pattern hair loss when medical treatments are insufficient. Requires skilled surgeon and realistic expectations. For alopecia areata: Olumiant (baricitinib) — FDA‑approved for severe alopecia areata in adults; intralesional corticosteroid injections are also standard and often effective for patchy disease. Supplements: Nutrafol and Viviscal — some women report benefit; evidence is mixed but they can help when nutritional deficiencies are contributing. Always check iron, vitamin D, B12 first. Important safety and diagnostic notes Get a proper diagnosis first — causes include androgenetic alopecia, telogen effluvium (stress, meds, childbirth), alopecia areata, thyroid disease, iron deficiency, and more. Tests commonly ordered: TSH, ferritin, CBC, and hormone testing if signs of PCOS. Avoid teratogenic medications (finasteride/Propecia is contraindicated in women who may become pregnant). Spironolactone and some oral meds require reliable contraception. Work with a board‑certified dermatologist or hair specialist (trichologist supervised by a dermatologist) for prescriptions, injections, PRP, or transplants. Suggested next steps Book an appointment with a dermatologist experienced in hair loss (in person or via reputable telederm). Get basic labs (TSH, ferritin, CBC; others as suggested). If you have female pattern hair loss, start topical minoxidil (Rogaine Women 5% Foam) and discuss spironolactone or low‑dose oral minoxidil if needed. Consider adjunct PRP or a laser device (HairMax/LaserCap) if you want non‑surgical enhancement. For rapid or patchy loss, ask about alopecia areata management (steroid injections, and for severe cases, Olumiant). If you tell me a bit about your symptoms (pattern of loss, how long, any recent stress/illness, age, pregnancy plans), I can suggest the most likely next step and what tests to ask your doctor for.

Mentioned in position 6 of 8

Read full answer with sources →

Public AI visibility history

Daily rank of Olumiant on our buyer intent questions, per category. A dash means the engines did not cite Olumiant at all that day. This record is permanent.

CategoryJun 11Jun 12Jun 13
Hair loss treatment#29

TL;DR

Olumiant (baricitinib) is a prescription medication developed by Eli Lilly and Incyte, originally approved for rheumatoid arthritis and later granted FDA approval for alopecia areata, making it the first systemic oral treatment for that condition. It is a JAK inhibitor available through licensed healthcare providers rather than direct-to-consumer channels. In WellRank's latest AI-answer index, Olumiant ranks tenth in the hair loss treatment category with 8% visibility, and the single AI mention captured in our corpus carries a positive tone.

Company Overview

Olumiant is a branded prescription drug co-developed by Eli Lilly and Incyte Corporation. The business model is pharmaceutical: the drug is manufactured and distributed through Eli Lilly, prescribed by dermatologists and rheumatologists, and dispensed via licensed pharmacies. It is not a telehealth platform itself, but it surfaces in telehealth and AI health-answer contexts as a treatment option discussed or prescribed through virtual care visits.

Product Features

  • Baricitinib 2 mg oral tablet for rheumatoid arthritis
  • Baricitinib 4 mg oral tablet approved for severe alopecia areata in adults
  • JAK1 and JAK2 inhibitor mechanism targeting inflammatory pathways
  • Once-daily oral dosing, distinguishing it from topical hair loss treatments
  • FDA Breakthrough Therapy designation history for alopecia areata indication
  • Studied and used in additional indications including COVID-19 hospitalized patients

Target Market

Olumiant is prescribed to adults with moderate-to-severe rheumatoid arthritis and adults with severe alopecia areata. For hair loss, it targets patients who have not responded adequately to other therapies. It is approved and primarily marketed in the United States, European Union, and other major markets worldwide.

Buyer Personas

  • An adult with severe alopecia areata who has tried topical minoxidil and other options without meaningful regrowth and is seeking an oral systemic treatment.
  • A rheumatoid arthritis patient whose disease is not adequately controlled on methotrexate or biologics and who needs an oral JAK inhibitor alternative.
  • A dermatologist or rheumatologist evaluating newer prescription options to discuss with patients during in-person or telehealth consultations.
  • A telehealth platform clinician looking to understand FDA-approved systemic treatments to include in a comprehensive hair loss care pathway.

Funding & Performance

Olumiant is a product of Eli Lilly and Company, a publicly traded global pharmaceutical corporation (NYSE: LLY). Revenue figures specific to Olumiant are reported in Lilly's quarterly earnings disclosures but are not broken out in detail here. Incyte receives royalties under their collaboration agreement.

Recent Developments

The FDA approval of baricitinib for severe alopecia areata marked a significant milestone as the first oral systemic therapy approved specifically for that condition, drawing considerable attention from dermatology and telehealth communities. Eli Lilly has continued to study baricitinib across other inflammatory and immune-mediated conditions. The alopecia areata approval has led to growing discussion of the drug in hair loss treatment contexts, which is reflected in its organic appearance in AI-generated health answers.

Competitive Landscape

In WellRank's co-mention data, Olumiant appears alongside Rogaine, Viviscal, Nutrafol, LaserCap, HairMax, Bernstein Medical, and Aldactone in AI answers about hair loss treatment. Most of those co-mentioned brands are over-the-counter supplements, topical treatments, or devices, while Aldactone (spironolactone) and Olumiant are prescription systemic options, placing Olumiant in a distinct tier. Its once-daily oral mechanism and FDA-approval status for alopecia areata differentiate it clearly from topical or nutraceutical competitors in that set.

Olumiant vs the brands AI recommends alongside it

The real competitive set in Hair loss treatment: brands the engines name in the same answers, ranked on the latest day.

BrandRankAI visibility
Olumiant logo
OlumiantThis brand
#29
8.3%
Aldactone logo
Aldactone

1 shared answers

#21
8.3%
Bernstein Medical logo
Bernstein Medical

1 shared answers

#28
8.3%
HairMax logo
HairMax

1 shared answers

#18
8.3%
LaserCap logo
LaserCap

1 shared answers

#27
8.3%

Email me when overtakes Olumiant

One email the day the ranks flip. Nothing else.

User Sentiment

Based on WellRank's current corpus, Olumiant's single captured AI mention carries a positive tone, with no neutral or cautious mentions recorded at this time. Broader public and clinical sentiment tends to reflect cautious optimism: patients and dermatologists recognize its novel mechanism and demonstrated efficacy in clinical trials for alopecia areata, while also noting the safety monitoring requirements typical of JAK inhibitors. The drug's prescription-only status means most consumer discussion occurs in clinical or patient-advocacy contexts rather than general wellness forums.

Pricing

Olumiant is a branded prescription medication and its list price is set by Eli Lilly; exact out-of-pocket costs vary significantly depending on insurance coverage, pharmacy benefits, and any applicable patient assistance programs offered by the manufacturer. Pricing is not published as a single stable figure and patients are generally directed to their pharmacy or insurer for cost details.

Sources cited around Olumiant

The sites engines cite in answers mentioning this brand. Win these, win the answer.

    Track Olumiant weekly

    One email a week: rank moves, new competitors, and the answers that changed. No noise.

    Work at Olumiant? Get your AI Visibility Audit.

    See every buyer intent question your customers ask AI, which ones you are losing, who wins them instead, and the exact sources driving those answers. You will finally understand your buyer intent and what Propel would do to win it.